---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010560"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:18:25.525834+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ZyVersa reports $14.1M net loss for 2022, cash $5.9M; plans VAR 200 trial in Q4 2023

## Summary
- No revenue in 2022; net loss of $14.1M combined (up 75% from $8.1M in 2021).
- Cash $5.9M as of Dec 31, 2022; expects to need additional financing to continue operations.
- Completed business combination with Larkspur Health in Dec 2022; began trading on Nasdaq under ZVSA.
- Plans investigator-initiated trial for VAR 200 in FSGS and up to two other renal indications in Q4 2023.
- IC 100 preclinical program to complete in 2023; IND submission expected Q2 2024.

## SEC filing metadata
- accession: 0001493152-23-010560
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/0001493152-23-010560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010560
- JSON: https://secwatch.observer/filing/0001493152-23-010560.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010560.txt

## Key facts
- Earnings Releases
  ZyVersa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA , or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drug candidates for the treatment of renal and inflammatory diseases with high unmet medical needs, today provides a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223010560/0001493152-23-010560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.